Prognosis assessment of CD44<sup>+</sup>/CD24<sup>-</sup> in breast cancer patients: a systematic review and meta-analysis.

Gu, Jingjing; Chen, Dandan; Li, Zhiqiang; Yang, Yongliang; Ma, Zhaoming; Huang, Guanhong

Prognosis assessment of CD44⁺/CD24^- in breast cancer patients: a systematic review and meta-analysis.

Gu, Jingjing; Chen, Dandan; Li, Zhiqiang; Yang, Yongliang; Ma, Zhaoming; Huang, Guanhong.

Afiliación

Gu J; Lianyungang Second People's Hospital Affiliated to Bengbu Medical College, Lianyungang, China.
Chen D; Lianyungang Second People's Hospital Affiliated to Bengbu Medical College, Lianyungang, China.
Li Z; Lianyungang Second People's Hospital Affiliated to Bengbu Medical College, Lianyungang, China.
Yang Y; Lianyungang Second People's Hospital Affiliated to Bengbu Medical College, Lianyungang, China.
Ma Z; Lianyungang Second People's Hospital Affiliated to Bengbu Medical College, Lianyungang, China. mazhm131@126.com.
Huang G; Lianyungang Second People's Hospital Affiliated to Bengbu Medical College, Lianyungang, China. hghlyg002@sina.com.

Arch Gynecol Obstet ; 306(4): 1147-1160, 2022 10.

Article en En | MEDLINE | ID: mdl-35435483

Asunto(s)

Antígeno CD24; Receptores de Hialuranos; Biomarcadores de Tumor/metabolismo; Antígeno CD24/genética; Antígeno CD24/metabolismo; Supervivencia sin Enfermedad; Humanos; Receptores de Hialuranos/metabolismo; Metástasis Linfática; Pronóstico; Modelos de Riesgos Proporcionales

Palabras clave

Breast cancer; CD44+/CD24−; Meta-analysis; Prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores de Hialuranos / Antígeno CD24 Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Arch Gynecol Obstet Asunto de la revista: GINECOLOGIA / OBSTETRICIA Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google